Bausch Health Companies (NYSE: BHC) has faced significant challenges, with its share price dropping 17% since the beginning of 2026. The company is grappling with a major patent cliff that threatens its highest-grossing drug’s exclusivity, potentially impacting its strategy to enhance shareholder value. Bausch aims to grow its business and reduce debt while planning to monetize a key “hidden asset.” These developments underscore the hurdles the company must navigate in the near future.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
